• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Intricon Corporation

    4/4/22 5:04:06 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care
    Get the next $IIN alert in real time by email
    SC 13G 1 iin13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Intricon Corporation

    (Name of Issuer)

     

     

    Common Stock, par value $1.00

    (Title of Class of Securities)

     

     

    46121H109

    (CUSIP Number)

     

     

    March 25, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 46121H109

     

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 667,169

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 667,169

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 667,169

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12. Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 46121H109

     

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 667,169

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 667,169

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 667,169

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12. Type of Reporting Person (See Instructions) IA, PN

     

     3 
    CUSIP No. 46121H109

     

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 587,915

     

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 587,915

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 587,915

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.3%

     

    12. Type of Reporting Person (See Instructions) PN

     

     4 
    CUSIP No. 46121H109

     

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 667,169

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 667,169

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 667,169

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.2%

     

    12. Type of Reporting Person (See Instructions) IN, HC

     

     5 
    CUSIP No. 46121H109

     

    Item 1.

     

    (a)Name of Issuer

    Intricon Corporation

     

    (b)Address of Issuer's Principal Executive Offices

    1260 Red Fox Road, Arden Hills, MN 55112

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    1611 S. Catalina Ave., Suite 309, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $1.00 (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 46121H109

     

     

     6 
    CUSIP No. 46121H109

     

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 9,272,840 shares of Common Stock outstanding as of February 28, 2022, as reported in the Form 10-K filed by the Issuer on March 7, 2022.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Beryl is the investment adviser to the Partnership and other private investment funds (collectively, the “Funds”) and other accounts. Beryl is the general partner of Beryl GP, which is also the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl and Beryl GP. The Funds hold the Stock for the benefit of their investors, and the Funds and Beryl’s other clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock. Other than the Partnership, no individual client's holdings of the Stock are more than five percent of the outstanding Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     7 
    CUSIP No. 46121H109

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 4, 2022

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By:  /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By: /s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     8 
    CUSIP No. 46121H109

     

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: April 4, 2022

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By:  /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By: /s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

    Get the next $IIN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giordano Nicholas A gifted 4,000 shares and returned 110,925 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:49:14 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Smith Philip Irving returned 16,327 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:43:53 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Gorder Mark Stephen returned 373,709 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:46:42 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intricon Announces Completion of Acquisition by an Affiliate of Altaris Capital Partners

    ARDEN HILLS, Minn., May 24, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced the completion of its acquisition by funds affiliated with Altaris Capital Partners, LLC (together with certain affiliated entities, "Altaris") for $24.25 per share in cash, or approximately $241 million on a fully diluted basis. The transaction was announced on February 28, 2022, and received approval from stockholders on May 24, 2022. As a result of the transaction, Intricon is now a privately he

    5/24/22 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Enters into Agreement to be Acquired by an Affiliate of Altaris Capital Partners for $241 Million

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, LLC (collectively with its affiliates, "Altaris"), an investment firm focused exclusively on the healthcare industry, will acquire the company. Under the terms of the agreement, Altaris will acquire all outstanding shares of Intricon for $24.25 per share in a transaction that values Intricon at an equ

    2/28/22 8:35:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    SEC Filings

    View All

    SEC Form 15-12B filed by Intricon Corporation

    15-12B - INTRICON CORP (0000088790) (Filer)

    6/3/22 10:36:21 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INTRICON CORP (0000088790) (Filer)

    5/25/22 3:55:57 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Intricon Corporation

    S-8 POS - INTRICON CORP (0000088790) (Filer)

    5/24/22 5:07:27 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley resumed coverage on IntriCon with a new price target

    B. Riley resumed coverage of IntriCon with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    2/26/21 9:37:25 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Financials

    Live finance-specific insights

    View All

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Third Quarter 2021 Results

    ARDEN HILLS, Minn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Highlights: Revenue of $31.1 million, a 13.5% increase compared to the prior year periodGross profit margin of 23.1%, compared to 26.3% in the prior year periodGAAP net income of $337,000 versus net income of $644,000 in the prior year periodNon-GAAP adjusted net income of $1.7 million versus $2.4 m

    11/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Announces CFO Departure and Preliminary Third Quarter 2021 Revenue

    ARDEN HILLS, Minn., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, announced today that Ellen Scipta has stepped down from her position as Chief Financial Officer, effective October 29, 2021. Annalee Lutgen, current Treasurer and Director of Finance, will serve as interim Chief Financial Officer effective upon Ms. Scipta's resignation as the company conducts its search for a permanent replacement. "We appreciate the contributions Ellen has made to Intricon during her tenure h

    10/29/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/26/22 4:04:17 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/23/22 4:14:23 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/19/22 4:06:37 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Leadership Updates

    Live Leadership Updates

    View All

    Intricon Appoints Kathleen Pepski to its Board of Directors Intricon Corporation

    ARDEN HILLS, Minn., March 22, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced the appointment of Kathleen Pepski to the company’s Board of Directors, effective March 19, 2021. “We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long

    3/22/21 8:00:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation Announces Appointment of Chief Financial Officer

    ARDEN HILLS, Minn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that Ellen Scipta has been appointed Chief Financial Officer (CFO), effective immediately. As a key member of Intricon's executive leadership team, Ms. Scipta will lead the company’s financial operations and aid the management team on growing Intricon. “We are extremely pleased to welcome a strong leader like Ellen to the Intricon team. Her unique skill set that blends engineering with extensive financial experience will be inva

    2/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care